Category Archives: Penny Stocks

Best Biotech Stocks For 2013

If you’re looking for a stock that could double over the next 12 months, your best bet is biotechnology. Using the Google (GOOG) screener, I found that 51 stocks with a market capitalization greater than $50 million had returned one-year gains of at least 100%. But what’s even more interesting is that biotechnology stocks account for 18 or 35% of the 51 stocks trading with at least a 100% gain over the last year. The top 5 gainers in the market, over the last year, are biotech stocks, and 9 of the top 20 were biotech. Therefore, it’s safe to say that if you’re looking for a stock with quick upside potential, biotechnology should be the first place you look. However, it can be difficult to identify the stocks that have this level of upside potential, which is what this article will attempt to identify.

This article is actually a two part series that will look at 10 stocks in the biotechnology industry that present the most upside potential from its current position. The stocks on this list are numbered from 10-1, with #1 having the most potential based on a number of possible factors, which include: clinical trials, low valuations, and even the likelihood for being acquired. The goal is to find the absolute most undervalued biotech stocks in the market that could very well return gains of more than 100% over the next 52 weeks.

Best Biotech Stocks For 2013: Amgen Inc.(AMGN)

Amgen Inc., a biotechnology medicines company, discovers, develops, manufactures, and markets human therapeutics based on advances in cellular and molecular biology for grievous illnesses primarily in the United States, Europe, and Canada. The company markets recombinant protein therapeutics in supportive cancer care, nephrology, and inflammation. Its principal products include Aranesp and EPOGEN erythropoietic-stimulating agents that stimulate the production of red blood cells; Neulasta and NEUPOGEN to stimulate the production of neutrophils, which is a type of white blood cell that helps the body to fight infections; and Enbrel, an inhibitor of tumor necrosis factor that plays a role in the body?s response to inflammatory diseases. The company also markets other products comprising Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin (TPO) receptor agonist that mimics endogenous TPO, the primary driver of platelet production. In addition, it provides Denosumab, a human monoclonal antibody that targets RANKL, an essential regulator of osteoclasts. Further, the company offers product candidates in mid-to-late stage development in a variety of therapeutic areas, including oncology, hematology, inflammation, bone, nephrology, cardiovascular, and general medicine consisting of neurology. It markets its products to healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies; consumers; and wholesale distributors of pharmaceutical products. The company has various collaborative arrangements with Pfizer Inc.; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited; Daiichi Sankyo Company, Limited; Array BioPharma Inc.; Kyowa Hakko Kirin Co. Ltd.; and Cytokinetics, Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

Advisors’ Opinion:

  • [By TheStreet Staff]The Amgen (AMGN) strategy of returning cash to shareholders in form of share buybacks, Dutch tender offers and dividends is abandoned in favor of ramped up acquisitions i.e. Gilead Sciences buying Pharmasset. Large-cap biotech firms start acting like Big Pharma — choosing to buy growth instead of seeking it from internal drug development.

Best Biotech Stocks For 2013: Sanofi(SNY)

sanofi-aventis engages in the discovery, development, and distribution of therapeutic solutions to improve the lives of everyone. The company offers a range of healthcare assets, including a broad-based product portfolio in prescription drugs, OTC/OTX, generics, vaccines, and animal health. It has a strategic alliance with Regulus Therapeutics Inc. to discover, develop, and commercialize micro-RNA therapeutics, initially in fibrosis. The company was founded in 1970 and is headquartered in Paris, France.

Advisors’ Opinion:

  • [By Michael]Sanofi is a global and diversified healthcare company. Cramer holds 2,600 shares of SNY stocks. SNY has a dividend yield of 5.40% and returned 7.19% since the beginning of this year. It has a market cap of $87.11B and a P/E ratio of 14.42. Ken Fisher invested nearly $600 million in SNY.

Best Biotech Stocks For 2013: Telik Inc (TELK)

Telik, Inc. (Telik), incorporated in 1988, is a clinical-stage drug development company focused on discovering and developing small molecule drugs to treat cancer. The Company discovers its product candidates using the Company’s drug discovery technology, Target-Related Affinity Profiling (TRAP). TELINTRA, its principal drug product candidate in clinical development, is a small molecule glutathione analog inhibitor of the enzyme glutathione S-transferase P1-1 (GST P1-1). TELCYTA, its other product candidate, is a small molecule cancer drug product candidate designed to be activated in cancer cells.

 

Clinical Product Development

 

TELINTRA is the Company’s lead small molecule product candidate in clinical development for the treatment of blood disorders, including cancer. It has a mechanism of action and acts by inhibiting GST P1-1, an enzyme that is involved in the control of cellular growth and differentiation. Inhibition of GST P1-1 results in the activation of the signaling molecule Jun kinase, a regulator of the function of blood precursor cells. Preclinical tests show that TELINTRA is capable of causing the death or apoptosis of leukemic or malignant blood cells, while stimulating the growth and development of normal blood precursor cells. TELINTRA has been studied in Myelodysplastic Syndrome (MDS) using two formulations. A liposomal formulation was developed for intravenous administration of TELINTRA and was used in Phase I and Phase II studies in MDS patients. The results from the Phase II intravenous liposomal TELINTRA clinical trials demonstrated that TELINTRA treatment was associated with improvement in all three types of blood cell levels in patients with all types of MDS, including those in intermediate and high-risk groups. An oral dosage formulation (tablet) was subsequently developed and results from a Phase I study with TELINTRA tablets showed clinical activity and the formulation to be well tolerated. In June 2011, the Company initiated a Phase II clinical trial to evaluate TELINTRA tablets. In October 2011, the Company initiated an additional Phase IIb clinical trial to evaluate TELINTRA tablets. ‘

 

The activity and safety profile of tablet formulation allowed the Company to complete a Phase II trial of TELINTRA tablets in MDS. The primary objective of the Phase II TELINTRA tablet study was to determine the efficacy of TELINTRA. A multivariate logistic regression analysis was conducted to identify MDS disease prognostic factors associated with erythroid improvement response rates, including prior MDS treatment, age, gender, the international prognostic scoring system (IPSS), risk, Eastern Cooperative Group performance status, years from MDS diagnosis, MDS World Health Organization subtypes, anemia only versus anemia plus other cytopenias, dose schedule and starting dose. Results from this study show that TELINTRA is the first GSTP1-1 enzyme inhibitor shown to cause clinically reductions in red blood cell transfusions, including transfusion independence in low to intermediate-1 risk MDS patients, as well as improvement in platelet count and white blood cell levels in certain patients. TELINTRA, administered orally twice daily, appeared to be convenient and flexible for chronic treatment administration.

 

TELCYTA is a small molecule drug product candidate that the Company is developed for the treatment of cancer. TELCYTA binds to GST. TELCYTA has been evaluated in multiple Phase II and Phase III clinical trials, including trials using TELCYTA as monotherapy and in combination regimens in ovarian, non-small cell lung, breast and colorectal cancer. Results from these clinical trials indicate that TELCYTA monotherapy was generally well-tolerated, with mostly mild to moderate side effects, particularly when compared to the side effects and toxicities of standard chemotherapeutic drugs. When TELCYTA was evaluated in combination with standard chemotherapeutic drugs, the tolerability of the combinations was similar to that expected of each drug alone.

 

Clinical activity including objective tumor responses and/or disease stabilization was reported in the TELCYTA Phase II trials; however, TELCYTA did not meet its primary endpoints in the Phase III studies. Positive results from a Phase I-IIa multicenter, dose-ranging study of TELCYTA in combination with carboplatin and paclitaxel as first-line therapy for patients with non-small cell lung cancer, or NSCLC, were published in a peer reviewed publication. Clinical data demonstrated positive results of TELCYTA in combination with carboplatin and paclitaxel in the treatment of first-line lung cancer followed by TELCYTA maintenance therapy. As of December 31, 2011, the Company had an on-going investigator-led study at a single site of TELCYTA in patients with refractory or relapsed mantle cell lymphoma, diffuse B cell lymphoma, and multiple myeloma.

 

Preclinical Drug Product Development

 

The Company has a small molecule compound, TLK60404, in preclinical development that inhibits both Aurora kinase and VEGFR kinase. Aurora kinase is a signaling enzyme whose function is required for cancer cell division, while VEGF plays a key role in tumor blood vessel formation, ensuring an adequate supply of nutrients to support tumor growth. These lead compounds prevented tumor growth in preclinical models of human colon cancer and human leukemia by inhibiting both Aurora kinase and VEGFR kinase. A development drug product candidate, TLK60404, has been selected.

 

The Company, using its TRAP technology has discovered TLK60357, a novel, potent small molecule inhibitor of cell division. TLK60357 inhibits the formation of microtubules that are necessary for cancer cell growth leading to persistent G2/M cancer cell cycle block and subsequent cell death. This compound demonstrates potent broad-spectrum anticancer activity against a number of human cancer cells. This compound also displays oral efficacy in multiple, standard preclinical models of cancer. TLK60596, a potent VGFR kinase inhibitor, blocks the formation of new blood vessels in tumors. Oral administration of TLK60596 to animal models of human colon cancer reduced tumor growth.

Best Biotech Stocks For 2013: Gentium SpA(GENT)

Gentium S.p.A., a biopharmaceutical company, focuses on the development and manufacture of its primary product candidate, defibrotide, an investigational drug based on a mixture of single-stranded and double-stranded DNA extracted from pig intestines. It develops defibrotide for the treatment and prevention of hepatic veno-occlusive disease (VOD), a condition that occurs when veins in the liver are blocked as a result of cancer treatments, such as chemotherapy or radiation, that are administered prior to stem cell transplantation. The company has completed a Phase III clinical trial of defibrotide for the treatment of severe VOD in the United States, Canada, and Israel; and a Phase II/III pediatric trial in Europe for the prevention of VOD. It also offers sulglicotide that is developed from swine duodenum, and has ulcer healing and gastrointestinal protective properties in South Korea; and urokinase, which is made from human urine to treat various vascular disorders, such as deep vein thrombosis and pulmonary embolisms. The company was formerly known as Pharma Research S.r.L. and changed its name to Gentium S.p.A. in July 2001. Gentium S.p.A. was founded in 1993 and is headquartered in Villa Guardia, Italy.

Advisors’ Opinion:

  • [By Roger]Gentium is considered one of the best biotechnology stocks on the market, and offers a ROE that is terrific. The stock has been rebounding and while not at the 52 week high again yet it is quickly gaining.

Best Biotech Stocks For 2013: Merck & Company Inc.(MRK)

Merck & Co., Inc. provides various health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. The company?s Pharmaceutical segment provides human health pharmaceutical products, such as therapeutic and preventive agents for the treatment of human disorders in the areas of bone, respiratory, immunology, dermatology, cardiovascular, diabetes and obesity, infectious diseases, neurosciences and ophthalmology, oncology, vaccines, and women’s health and endocrine. This segment also offers human health vaccines, such as preventive pediatric, adolescent, and adult vaccines. Its Animal Health segment discovers, develops, manufactures, and markets animal health products. This segment offers antibiotics, anti-inflammatory products, vaccines, products for the treatment of fertility disorders, and parasiticides for cattle, swine, horses, poultry, dogs, cats, salmons, and fish. The Consumer Care segment develops, manufac tures, and markets over-the-counter, foot care, and sun care products. Its over-the-counter product line includes non-drowsy antihistamines; treatment for occasional constipation; decongestant-free cold/flu medicine for people with high blood pressure; nasal decongestant spray; and treatment for frequent heartburn. This segment?s foot care products comprise topical antifungal, and foot and sneaker odor/wetness products; and sun care products include sun care lotions, sprays and dry oils; and sunburn relief products. The company serves drug wholesalers and retailers, hospitals, government agencies, physicians, physician distributors, veterinarians, animal producers, and managed health care providers, as well as food chain and mass merchandiser outlets in the United States and Canada. Merck & Co., Inc. was founded in 1891 and is headquartered in Whitehouse Station, New Jersey.

Advisors’ Opinion:

  • [By McWillams]Merck & Co. Inc. (NYSE: MRK : 31.91, 0.05) reported net income of $2.02 billion, or 65 cents per share in its fiscal 2011 second quarter, compared to net income of $752 million or 24 cents a year ago. Analysts had estimated earnings of 95 cents per share for the firm. The company’s revenue rose 7 percent to $12.15 billion, better than analysts’ forecast of $11.82 billion. Shares closed Thursday’s trading at $34.93.
  • [By Smart Money]Forward P/E: 7.8.

     

    Five-year average forward P/E: 13.7.

    Discount to five-year average: 46%.

    The market’s shift away from defensive stocks in sectors like pharmaceuticals and the Obama administration’s proposed health care reforms are just a couple of issues weighing on Merck (MRK, news, msgs). Shares in the Whitehouse Station, N.J., company are also being hobbled by company-specific problems, such as disappointing sales of asthma treatment Singulair, its best-selling drug, as well as increased competition, patent expirations and a pipeline of drugs with poor prospects for Food and Drug Administration approval.

    Fortunately for Merck investors, the company’s pending acquisition of Schering-Plough (SGP, news, msgs) should go a long way toward easing many of these problems, especially Merck’s poor drug pipeline and its ability to remain competitive, says Morningstar analyst Damien Conover. “Merck greatly improved its long-term outlook by agreeing to acquire Schering-Plough,” the analyst says.

Best Biotech Stocks For 2013: Cell Therapeutics Inc (CTIC.A)

Cell Therapeutics, Inc. (CTI), incorporated in 1991, develops, acquires and commercializes treatments for cancer. The Company’s research, development, acquisition and in-licensing activities concentrate on identifying and developing new ways to treat cancer. As of December 31, 2011, CTI focused its efforts on Pixuvri (pixantrone dimaleate) (Pixuvri), OPAXIO (paclitaxel poliglumex) (OPAXIO), tosedostat, brostallicin and bisplatinates. As of December 31, 2011, it developed Pixuvri, an anthracycline derivative for the treatment of hematologic malignancies and solid tumors. Another late-stage drug candidate of the Company, OPAXIO, is being studied as a potential maintenance therapy for women with advanced stage ovarian cancer, who achieve a complete remission following first-line therapy with paclitaxel and carboplatin. As of December 31, 2011, it also developed tosedostat in collaboration with Chroma Therapeutics, Ltd. (Chroma). On May 31, 2012, CTI completed its acquisi tion gaining worldwide rights to S*BIO Pte Ltd.’s (S*BIO) pacritinib.

Pixuvri

As of December 31, 2011, the Company developed Pixuvri, an aza-anthracenedione derivative, for the treatment of non-Hodgkin’s lymphoma (NHL), and various other hematologic malignancies, and solid tumors. Pixuvri was studied in the Company’s EXTEND, or PIX301, clinical trial, which was a phase III single-agent trial of Pixuvri for patients with relapsed, refractory aggressive NHL who received two or more prior therapies and who were sensitive to treatment with anthracyclines. On September 28, 2011, CTI announced that a second independent radiology assessment of response and progression endpoint data from its PIX301 clinical trial of Pixuvri was achieved with statistical significance. The results of the EXTEND trial met its primary endpoint and showed that patients randomized to treatment with Pixuvri achieved a significantly higher rate of confirmed and unconfirmed co mplete response compared to patients treated with standard c! hemotherapy had a significantly increased overall response rate and experienced a statistically significant improvement in median progression free survival. Pixuvri had predictable and manageable toxicities when administered at the proposed dose and schedule in the EXTEND clinical trial in heavily pre-treated patients. In March 2011, the Company initiated the PIX-R trial to study Pixuvri in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Pixuvri has also been studied in patients with HER2-negative metastatic breast cancer who have tumor progression after at least two, but not more than three, prior chemotherapy regimens. In the second quarter of 2010, the NCCTG opened this phase II study for enrollment. The study is closed to accrual and results are expected to be reported by the NCCTG later in 2012.

OPAXIO

OPAXIO is the Company’s biologically-enhanced chemotherapeutic agent that links pacli taxel to a biodegradable polyglutamate polymer, resulting in a new chemical entity. As of December 31, 2011, the Company focused its development of OPAXIO on ovarian, brain, esophageal, head and neck cancer. OPAXIO was designed to improve the delivery of paclitaxel to tumor tissue while protecting normal tissue from toxic side effects. In November 2010, results were presented by the Brown University Oncology Group from a phase II trial of OPAXIO combined with temozolomide (TMZ), and radiotherapy in patients with newly-diagnosed, high-grade gliomas, a type of brain cancer. The trial demonstrated a high rate of complete and partial responses and a high rate of six month progression free survival (PFS). Based on these results, the Brown University Oncology Group has initiated a randomized, multicenter, phase II study of OPAXIO and standard radiotherapy versus TMZ and radiotherapy for newly diagnosed patients with glioblastoma with an active gene termed MGMT that reduces respons iveness to TMZ. A phase I/II study of OPAXIO combined with r! adiothera! py and cisplatin was initiated by SUNY Upstate Medical University, in patients with locally advanced head and neck cancer.

Tosedostat

In March 2011, the Company entered into a co-development and license agreement with Chroma Therapeutics, Ltd. (Chroma), providing the Company with marketing and co-development rights to Chroma’s drug candidate, tosedostat, in North, Central and South America. Tosedostat is an oral, aminopeptidase inhibitor that has demonstrated anti-tumor responses in blood related cancers and solid tumors in phase I-II clinical trials. Interim results from the phase II OPAL study of tosedostat in elderly patients with relapsed or refractory acute myeloid leukemia (AML) showed that once-daily, oral doses of tosedostat had predictable and manageable toxicities and results demonstrated response rates, including a high-response rate among patients who received prior hypomethylating agents, which are used to treat myelodysplastic synd rome (MDS), a precursor of AML.

Brostallicin

As of December 31, 2011, the Company developed brostallicin through its wholly owned subsidiary, Systems Medicine LLC, which holds rights to use, develop, import and export brostallicin. Brostallicin is a synthetic deoxyribonucleic acid (DNA) minor groove binding agent that has demonstrated anti-tumor activity and a favorable safety profile in clinical trials, in which more than 230 patients have been treated as of December 31, 2011. The Company uses a genomic-based platform to guide the development of brostallicin. A phase II study of brostallicin in relapsed, refractory soft tissue sarcoma met its predefined activity and safety hurdles and resulted in a first-line phase II clinical trial study that was conducted by the European Organization for Research and Treatment of Cancer (EORTC).

The Company competes with Bristol-Myers Squibb Company, Sanofi-Aventis, Pfizer, Roche Group, Genentech, Inc., Astellas Pharma, Eli Lilly and Company, Celgene, Telik! , Inc., T! EVA Pharmaceuticals Industries Ltd. and PharmaMar.

Stocks To Invest In 2013

Now, I know that lots of my readers are already yelling at their computer screens — “Buy and hold is dead!” goes the cry, and that has certainly been increasingly the sentiment of the market over the last few years … especially since, in so many stocks, “buy and hold” has meant “buy and watch them go down over time.”

Any inflexible strategy is bound to have problems and down years … heck, even the flexible ones have down years … but still, there’s a certain part of me that loves “buy and hold.” Missing the worst days and the worst crashes in the market is great if your stop losses get you out before the bottom hits, but not missing the best days has historically been more important, if only because those who sell as their stocks go down are generally terrible at buying back in before the stock or market has fully rebounded or recovered (no not you — I mean everyone else).

In a world where I have no confidence in the overall direction of the market, I can at least have some confidence in big businesses with stable earnings, growing revenues, and growing dividends. Maybe we can’t hold them forever, but most of my best picks over the long haul have been stocks that I’ve held through up and down markets (and watched the dividends compound dramatically, in some cases) … and my biggest mistakes have mostly been selling stocks that, after I sold them, beat the market handily. That said, I also have held on to my share of stinkers for far too long, so maybe this is just a psychological flaw for your friendly neighborhood Gumshoe.

 

Stocks To Invest In 2013: FSI International Inc.(FSII)

FSI International, Inc. designs, manufactures, markets, and supports equipment used in the fabrication of microelectronics. The company primarily offers surface conditioning equipment that uses wet, cryogenic, and other chemistry techniques to clean, strip, or etch the surfaces of silicon wafers; and refurbished microlithography products to deposit and develop light sensitive films. Its products include spray cleaning systems, which remove unwanted films and contaminants from the surface of semiconductor wafers at various stages in the microelectronic device fabrication process; single wafer cleaning systems that clean semiconductor wafers in a closed chamber and single wafer environment; cryokinetic processing systems, which remove non-chemically bonded particles from the surface of a microelectronic device; immersion cleaning systems that clean silicon wafers by immersing wafers in multiple tanks filled with process chemicals; and microlithography systems, which deposit polyimide resist and photoresist, light-sensitive, and etch-resistant materials, as well as develop the deposited material after exposure. The company also provides system and subsystem upgrade packages, spare part kits, individual spare part components, robot refurbishment and replacement, and support services to extend the life of previously purchased and installed systems. FSI International, Inc. offers its products under the ZETA, MERCURY, ORION, ANTARES, and POLARIS names. The company sells its products directly to the microelectronics manufacturers in North America, Europe, Japan, and the Asia Pacific region. FSI International, Inc. was founded in 1973 and is headquartered in Chaska, Minnesota.

Stocks To Invest In 2013: Texas Pacific Land Trust(TPL)

Texas Pacific Land Trust engages in the sale, lease, and management of land in the United States. It also retains oil and gas royalties, and involves in temporary cash investments. The company leases land to the ranching industry for grazing purposes. As of March 31, 2011, it owned surface rights in 949,355 acres of land in 20 counties in Texas; and 318 town lots in Loraine. The company also owned a 1/128 nonparticipating perpetual oil and gas royalty interest under 85,414 acres of land; and a 1/16 nonparticipating perpetual oil and gas royalty interest under 386,988 acres of land in the western part of Texas. Texas Pacific Land Trust was founded in 1888 and is based in Dallas, Texas.

Stocks To Invest In 2013: Guardian Exploration Inc (GX.V)

Guardian Exploration Inc. engages in the acquisition, exploration, and development of petroleum and natural gas properties in western Canada and the state of Montana. It holds a farm-in agreement with Deckland Inc. to earn a 50% working interest in the well located in the Jenner area of Alberta, Canada. The company was formerly known as Guardian Resources Inc. and changed its name to Guardian Exploration Inc. in May 2001. Guardian Exploration Inc. was incorporated in 2001 and is headquartered in Calgary, Canada.

Stocks To Invest In 2013: Nuveen Select Tax Free Income Portfolio II(NXQ)

Nuveen Select Tax-Free Income Portfolio 2 is a closed-ended fixed income mutual fund launched by Nuveen Investments Inc. It is co-managed by Nuveen Fund Advisors, Inc and Nuveen Asset Management, LLC. The fund invests in the fixed income markets of United States. It invests in the investment-grade municipal securities rated Baa and BBB or better. The fund benchmarks the performance of its portfolio against the Standard & Poor?s (S&P) National Municipal Bond Index and Lipper General and Insured Unleveraged Municipal Debt Funds Average. Nuveen Select Tax-Free Income Portfolio 2 was formed on May 21, 1992 and is domiciled in the United States.

Stocks To Invest In 2013: TRC Companies Inc.(TRR)

TRC Companies, Inc. provides consulting, engineering, and construction management services in the United States. Its Energy segment offers program design, program management, quality control, engineering, financial tracking, and reporting services to energy companies, utilities, other commercial entities, and state and federal governments. This segment undertakes projects comprising upgrade and new construction for electrical transmission and distribution systems, energy efficiency program design and management, and alternative energy development, as well as provides services to support energy savings projects. The company?s Environmental segment involves in the environmental management of buildings, air quality measurements and modeling potential air pollution impacts, assessment and remediation of contaminated sites and buildings, solid waste management, environmental compliance auditing and strategic due diligence, environmental licensing and permitting various project s, and natural and cultural resource assessment and management. This segment serves industrial, transportation, energy, and natural resource companies, as well as federal, state, and municipal agencies. Its Infrastructure segment offers services relating to the expansion of infrastructure capacity, the rehabilitation of overburdened and deteriorating infrastructure systems, and the management of risks related to security of public and private facilities. This segment?s primary services comprise roadway, bridge, and related surface transportation design; structural design of bridges; construction engineering inspection and construction management for roads and bridges; civil engineering services for municipalities and public works departments; geotechnical engineering services; and security services. The Infrastructure segment serves state and municipal governments, as well as commercial developers. TRC Companies, Inc. was founded in 1969 and is based in Lowell, Massachusett s.

Stocks To Invest In 2013: ADDvantage Technologies Group Inc.(AEY)

ADDvantage Technologies Group, Inc., through its subsidiaries, distributes and services a range of electronics and hardware products for the cable television industry. The company provides new, surplus-new, and refurbished products in various brands, including Cisco, Motorola and Arris Solutions for use in connection with video, telephone and internet data signals. It offers headend products, including digital and analog satellite receivers, integrated receiver/decoders, demodulators, modulators, antennas and antenna mounts, amplifiers, equalizers, and processors for signal acquisition, processing, and manipulation for further transmission; fiber products comprising optical transmitters, fiber-optic cable, receivers, couplers, splitters, and compatible accessories for transmitting the output of cable system headend to virus locations using fiber-optic cables; and access and transport products, such as transmitters, receivers, line extenders, broadband amplifiers, direction al taps and splitters for use in permiting signals to travel from the headend to their destination in a home, apartment, hotel room, office or other terminal location. The company also provides customer premise equipment consisting of digital converter boxes and modems to receive, record, and transmit video, data, and telephony signals; and hardware equipment, such as test equipment, connector, and cable products. In addition, it offers Fujitsu Frontech North America encoders, decoders, and other media solutions products primarily for use in the broadcast industry. The company markets and sells its products to franchise and private MSOs, telephone companies, system contractors, and other resellers primarily in the United States, Canada, Central America, Mexico, and rest of South America. ADDvantage Technologies Group, Inc.was founded in 1989 and is based in Broken Arrow, Oklahoma.

Stocks To Invest In 2013: Derma Sciences Inc.(DSCI)

Derma Sciences, Inc. operates as a medical technology company. The company provides advanced wound care products, including Medihoney dressings that are used for the management of non-chronic and hard-to-heal wounds, such as chronic ulcers, burns, and post-operative wounds; Bioguard dressings that are used for prophylactic use in the prevention of hospital or community acquired infections through wound sites; Algicell Ag, antimicrobial dressings; Xtrasorb dressings that convert fluid within the dressings to a gel and lock the exudates into the dressings; TCC-EZ, a dressing system for the management of diabetic foot ulcers; and occlusive dressings, such as hydrocolloids, foams, hydrogels, alginates, additional silver antimicrobial dressings, cleansers, and Dermagran products. It also offers traditional wound care products, such as of gauze sponges and bandages, non-adherent impregnated dressings, retention devices, paste bandages, and other compression devices, as well as a dhesive bandages and related first aid products. In addition, the company provides pharmaceutical wound care products, including DSC127, an angiotensin analog for use in wound healing and scar reduction. It markets wound closure strips, nasal tube and catheter fasteners, barrier creams and ointments, antibacterial cleansing foams and sprays, shampoos and body washes, hand sanitizers, bath additives, body oils, and moisturizers to doctors, clinics, nursing homes, hospitals, home healthcare agencies, and other institutions. The company sells its products to health care providers, such as wound care centers, extended care facilities, acute care facilities, home health care agencies, and physicians? offices through direct sales representatives in the United States, Canada, and the United Kingdom; retail channels; manufacturers? representatives and independent distributors in international markets. Derma Sciences, Inc. was founded in 1984 and is headquartered in Princeton, New Jersey.

Best Company To Invest In 2013

Now, I know that lots of my readers are already yelling at their computer screens — “Buy and hold is dead!” goes the cry, and that has certainly been increasingly the sentiment of the market over the last few years … especially since, in so many stocks, “buy and hold” has meant “buy and watch them go down over time.”

Any inflexible strategy is bound to have problems and down years … heck, even the flexible ones have down years … but still, there’s a certain part of me that loves “buy and hold.” Missing the worst days and the worst crashes in the market is great if your stop losses get you out before the bottom hits, but not missing the best days has historically been more important, if only because those who sell as their stocks go down are generally terrible at buying back in before the stock or market has fully rebounded or recovered (no not you — I mean everyone else).

In a world where I have no confidence in the overall direction of the market, I can at least have some confidence in big businesses with stable earnings, growing revenues, and growing dividends. Maybe we can’t hold them forever, but most of my best picks over the long haul have been stocks that I’ve held through up and down markets (and watched the dividends compound dramatically, in some cases) … and my biggest mistakes have mostly been selling stocks that, after I sold them, beat the market handily. That said, I also have held on to my share of stinkers for far too long, so maybe this is just a psychological flaw for your friendly neighborhood Gumshoe.

Best Company To Invest In 2013: Fresh Del Monte Produce Inc.(FDP)

Fresh Del Monte Produce Inc., through its subsidiaries, produces, transports, sources, markets, and distributes fresh and fresh-cut fruit and vegetables worldwide. It also offers prepared fruit and vegetables, juices, beverages, snacks, and poultry and meat products. The company provides various fresh-cut fruit products, such as bananas, pineapples, melons, tomatoes, grapes, apples, pears, peaches, plums, nectarines, cherries, citrus, avocados, blueberries, kiwi, strawberries, plantains, mangos, and fruit cocktail; and fresh-cut vegetable products primarily consisting of potatoes, onions, bell peppers, and cucumbers, as well as prepared salads, such as coleslaw and potato salad. In addition, Fresh Del Monte Produce engages in ocean freight; and manufacture of plastics and box products comprising bins, trays, bags, and boxes. It offers fresh produce under the DEL MONTE, UTC, and Rosy brands; and prepared fruits and vegetables, juices, beverages, and snacks under the DEL MON TE, Fruit Express, Just Juice, and Fruitini brands. The company markets and distributes its products to retail stores, food clubs, wholesalers, distributors, and foodservice operators. Fresh Del Monte Produce Inc. was founded in 1886 and is based in George Town, Cayman Islands.

Advisors’ Opinion:

  • [By Zacks]Fresh Del Monte Produce Inc. (FDP) announced an earnings per share surprise of 110% for its first quarter, fueled by product line restructuring and tighter cost controls. Adjusted earnings per share of 84 cents jumped from the prior year’s 28 cents and eclipsed the consensus of 40 cents. Net sales decline slightly due to aggressive efforts to improve the North American performance of its “Other Fresh Produce” business segment.

    Shares of the fruit and vegetable company gained approximately 16.5% last week as 52-week highs were reached on Apr 30 and May 1. Earnings estimates for this year have moved forward in the past seven days to $1.06. Fresh Del Monte Produce is encouraged by its best quarter in two years, and believes it is seeing the beginning of a turnaround that will leave it well-positioned for long-term growth.

Best Company To Invest In 2013: Huron Consulting Group Inc.(HURN)

Huron Consulting Group Inc. provides operational and financial consulting services in the United States. Its Health and Education Consulting segment develops and implements solutions to help clients address financial management, strategy, operational and organizational effectiveness, research administration, and regulatory compliance; and offers consulting services related to organization performance improvement, revenue cycle improvement, turnarounds, merger or affiliation strategies, labor productivity, non-labor cost management, information technology, patient flow improvement, physician practice management, interim management, clinical quality and medical management, and governance and board development to hospitals, health systems, physicians, managed care organizations, academic medical centers, colleges, universities, and pharmaceutical and medical device manufacturers. The company?s Legal Consulting segment provides strategic and management consulting, cost managem ent, and technology and information management, including matter management, records, document review, and discovery services to assist law departments and law firms. This segment also offers V3locity solution, which delivers streamlined e-discovery process; and IMPACT solution that delivers sustainable cost reductions. Its Financial Consulting segment assists corporations with accounting and financial reporting matters, and provides financial analysis in restructuring and turnaround situations, as well as consults with companies in the areas of corporate governance, Sarbanes Oxley compliance, and internal audit. Huron Consulting Group Inc. serves various industries, including healthcare, education, professional services, pharmaceutical, technology, transportation services, telecommunications, financial services, electronics, consumer products, governmental, energy and utilities, and industrial manufacturing. The company was founded in 2002 and is headquartered in Chicago, I llinois.

Advisors’ Opinion:

  • [By Zacks]Huron Consulting Group Inc. (HURN) is a leading provider of financial and operational consulting services that gained 15.4% last week. The company reported first-quarter earnings per share of 55 cents on revenues of $116 million. Earnings bettered the consensus by approximately 7.8% and surged from the previous year, while revenues soared 87% from the first quarter of 2006’s $62.2 million. Huron Consulting Group reached a 52-week high on May 3 while earnings estimates for this year improved 1.3% in the past seven days. The company continues to experience increased demand across its service offerings, and is optimistic that it will continue for the remainder of 2007. Huron Consulting Group believes it is well-positioned for this year and beyond, as evidenced by the decision to boost its full year outlook.

Best Company To Invest In 2013: Cooper Tire & Rubber Company(CTB)

Cooper Tire & Rubber Company, together with its subsidiaries, manufactures and markets replacement tires in North America and internationally. It operates in two segments, North American Tire Operations and International Tire Operations. The North American Tire Operations segment produces and distributes passenger car and light truck tires, as well as tires for racing, medium trucks, and motorcycles to independent tire dealers, wholesale distributors, regional and national retail tire chains, and other large automotive product retail chains. This segment sells its products through three own retail stores. The International Tire Operations segment manufactures and markets passenger car, light truck, motorcycle, light vehicle tires, radial and bias medium truck tires, and racing tires and tire retread material to markets worldwide. The company was founded in 1913 and is based in Findlay, Ohio.

Advisors’ Opinion:

  • [By Zacks]Cooper Tire & Rubber Company (CTB) reversed a year-ago loss with first-quarter earnings of 33 cents. The result also bettered the consensus by as much as 312%. Total sales moved forward 16% to $689 million, versus $597 million in the first quarter of 2006. Cooper Tire & Rubber said it continued to benefit from the cost reduction and profit improvement initiatives announced last September. Furthermore, it was helped by improved price and mix in North America, and increased tire unit sales in Europe and Asia.

    Shares of the company gained 12% last week, making it one of the top-performing Zacks #1 Rank companies. It also reached a 52-week high on the day of its report. Looking forward, Cooper Tire & Rubber expects to build on the momentum of the first quarter, as conditions and opportunities suggest a strong 2007. Over the past seven days, earnings estimates for this year have moved forward approximately 25% to 98 cents.

Best Company To Invest In 2013: Life Partners Holdings Inc(LPHI)

Life Partners Holdings, Inc., through its subsidiary, Life Partners, Inc., operates in the secondary market for life insurance in the United States. It facilitates life settlement transactions by identifying, examining, and purchasing the policies as agent for the purchasers. The company?s financial transactions involve the purchase of life insurance policies at a discount to their face value for investment purposes. It serves institutional purchasers, which include investment funds designed to acquire and hold life settlements; and retail purchasers, such as high net worth individuals. The company was founded in 1971 and is based in Waco, Texas.

Advisors’ Opinion:

  • [By Zacks]Life Partners Holdings, Inc. (LPHI) is engaged in the secondary market for life insurance. The company gained almost 27.5% last week to become the top-performing Zacks #1 Rank company. It was also a top performer in the week ended Apr 20. Over the past month, earnings estimates for the year ending February 2008 are up approximately 22.7%.

    Life Partners Holdings began this month by reached 52-week highs each day from May 2 through May 4. Last month, the company announced that it expects net income to surge 215% for fiscal 2007. This is attributed to an exceptional increase in net income beginning in the third quarter and continuing into the fourth quarter. For its fiscal fourth-quarter, earnings per share are expected at 22 cents, which would mark significant advances from both the year-ago performance and Wall Street expectations. The company plans to officially report its earnings later this month.